REBECCA Real-world Early BrEast CanCer mAnagement

A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

NCT00717405 ·Status: COMPLETED ·Phase: PHASE2

Retroprospective Real Life Observatory of Eribulin

NCT02393287 ·Status: COMPLETED

Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

NCT07180693 ·Status: RECRUITING

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

NCT03462251 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

NCT02149524 ·Status: COMPLETED ·Phase: PHASE3

Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.

NCT07243002 ·Status: RECRUITING

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

NCT06188559 ·Status: COMPLETED ·Phase: PHASE2

UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy

NCT00189631 ·Status: UNKNOWN ·Phase: PHASE3

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

NCT05912062 ·Status: UNKNOWN

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751 ·Status: COMPLETED ·Phase: PHASE2

Lynparza Breast Cancer Clinical Experience Investigation

NCT03590938 ·Status: COMPLETED

A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

NCT02613208 ·Status: COMPLETED

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

NCT02402712 ·Status: COMPLETED ·Phase: PHASE3

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

NCT02123823 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis

NCT01377363 ·Status: COMPLETED

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

NCT02675231 ·Status: COMPLETED ·Phase: PHASE2

Breast Cancer With Over-expression of erbB2-BRAINSTORM

NCT01064349 ·Status: COMPLETED

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

NCT00528567 ·Status: COMPLETED ·Phase: PHASE3

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

NCT01652560 ·Status: UNKNOWN

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891 ·Status: RECRUITING ·Phase: PHASE2

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

NCT01250379 ·Status: COMPLETED ·Phase: PHASE3

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

NCT01240421 ·Status: APPROVED_FOR_MARKETING

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

NCT03433313 ·Status: COMPLETED ·Phase: PHASE3

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

NCT06962969 ·Status: COMPLETED